We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Baxter International (BAX) Beats Q3 Earnings & Sales
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its third quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by of 44 cents and increased from 41 cents in the year-ago quarter.
Revenues: Baxter posted sales of $2,558 million, beating the Zacks Consensus Estimate for revenues of $2,545 million. At constant currency (cc), revenues increased 4% on a year-over-year basis.
Key Stats: Hospital products sales increased 3% at cc, while renal products went up 6% from the year-ago quarter.
Major Factors: Hospital Products sales were driven by solid demand for IV solutions, nutritional therapies, pharmacy injectables and IV access administration sets. Renal products sales were driven by peritoneal dialysis products as well as increased demand globally for continuous renal replacement therapies.
Stock Price: Following the earnings release, share price rose 2.48% in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Baxter International (BAX) Beats Q3 Earnings & Sales
Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its third quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by of 44 cents and increased from 41 cents in the year-ago quarter.
Revenues: Baxter posted sales of $2,558 million, beating the Zacks Consensus Estimate for revenues of $2,545 million. At constant currency (cc), revenues increased 4% on a year-over-year basis.
Key Stats: Hospital products sales increased 3% at cc, while renal products went up 6% from the year-ago quarter.
Major Factors: Hospital Products sales were driven by solid demand for IV solutions, nutritional therapies, pharmacy injectables and IV access administration sets. Renal products sales were driven by peritoneal dialysis products as well as increased demand globally for continuous renal replacement therapies.
BAXTER INTL Price
BAXTER INTL Price | BAXTER INTL Quote
Stock Price: Following the earnings release, share price rose 2.48% in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>